Sign in
WithdrawnNo phase

SmartWatch ECG Evaluation Trial I

Key facts

Who runs it
University of Oklahoma
Where
Oklahoma City, United StatesSee the site
Trial code
Status
Withdrawn
Started
Dec 2023
Ended
18 Apr 2024
Type of study
Interventional
Treatments tested
  • We propose to validate these smartwatch ECG functions to support FDA submissions
Record updated
22 May 2024
Why it stopped
The manufacturer who was to provide the study devices decided not to do so.

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Male or female > 18 years of age
  • Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures
  • Being seen in the OU Cardiac Electrophysiology Outpatient Clinic

Who cannot take part

  • Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and/or compromise the quality of the clinical trial
  • Inability or refusal of the patient and/or the patient's legally acceptable representative to provide written informed consent for any reason

Where in United States

  • University of Oklahoma Health Sciences CenterOklahoma City, United States

About the trial

What the trial wants to find out

This is a single-center, non-randomized study to collect validation data for submission to the Food and Drug Administration (FDA) to support a 510(k) device clearance for a smartwatch ECG.

The group in the trial

  • Screen groupTreatment being tested

    This is a single-center, non-randomized open study with a single-patient clinical trial design (i.e., the patients serve as their own control).

    Treatment: We propose to validate these smartwatch ECG functions to support FDA submissions

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
22 May 2024